What Does The Future Hold? GLP-1s, ICH, GCP, CAR-T, AI & More

By Darcy Grabenstein

Our yearly outlook takes an in-depth look at the forces set to influence the life sciences landscape in 2026, spanning everything from clinical study design and patient enrollment to trial transparency and reporting requirements. Informed by data from Citeline and perspectives from industry experts, this analysis examines key trends, potential obstacles, and new opportunities that are expected to shape pharmaceutical and biotechnology organizations in the coming year.

As experts across sectors share their expectations for 2026, life sciences leaders are also preparing for meaningful change. Gaining early awareness of these developments can support sponsors and clinical teams in making smarter strategic choices, improving trial operations, and strengthening patient-centered approaches.

Read on for practical insights into the future of clinical development, including shifts in study planning, novel patient recruitment strategies, and evolving standards for disclosure and transparency. Get ahead of what’s next and understand how the pharma industry is poised to evolve.